Justin F. Gainor, MD, discusses the latest advancements with immune checkpoint inhibitors for the treatment of patients with non—small cell lung cancer.
Justin F. Gainor, MD, director of the Center for Thoracic Cancers and Targeted Immunotherapy at Massachusetts General Hospital, discusses the latest advancements with immune checkpoint inhibitors for the treatment of patients with nonsmall cell lung cancer (NSCLC).
Checkpoint inhibitors have transformed the management of advanced NSCLC, where the agents have been moved to earlier lines in the disease course, Gainor says. The first evidence to demonstrate benefit in this setting, which ultimately launched further evaluation, was thephase III PACIFIC trial. Patients with locally advanced NSCLC who completed the standard of care chemotherapy and radiation went on to receive a checkpoint inhibitor, durvalumab (Imfinzi), as consolidation therapy. This led to an improvement in both the progression-free survival and overall survival rates.
Peritoneal RFS May Be a Stronger Predictor of OS in CRC Peritoneal Metastasis
March 27th 2024In an interview with Targeted Oncology, Muhammad Talha Waheed, MBBS, discussed research on the reliability of using recurrence-free survival as an efficacy end point for trials evaluating patients with colorectal cancer peritoneal metastasis.
Read More
Integrating New Therapies With Autologous Stem Cell Transplant in Myeloma
March 26th 2024Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed how the role of autologous stem cell transplant is evolving in the myeloma treatment landscape with the emergence of CAR T-cell therapies and bispecifics.
Read More
Amivantamab/Lazertinib Still Effective in EGFRm NSCLC Despite Dose Interruptions
March 26th 2024According to a subset analysis of the phase 3 MARIPOSA trial, dose interruptions during the course of amivantamab and lazertinib treatment were still effective in EGFR-mutant non-small cell lung cancer.
Read More